论文部分内容阅读
目的观察CHOP方案一线治疗维吾尔族(维族)、汉族不同亚型弥漫大B细胞淋巴瘤(DLBCL)的临床疗效和不良反应。方法收集6年间经病理确诊DLBCL并经CHOP方案一线治疗至少6周期的维、汉族住院患者共167例,用Hans方法检测分为GCB型和非GCB型(non-GCB型)两组,比较临床疗效及不良反应。结果维、汉族DLBCL免疫分型均为non-GCB型明显多于GCB型;维、汉族GCB型DLBCL疗效均明显优于nonGCB型;维、汉族间同亚型DLBCL有效率差异无统计学意义;维、汉两族化疗不良反应主要表现为胃肠道反应、轻中度骨髓抑制和神经毒性,不良反应发生率相近。结论常规免疫亚型均是判断维族及汉族DLBCL患者近期疗效的重要指标,并且两族non-GCB型患者CHOP方案一线化疗疗效均有限,建议制定更有效化疗方案。
Objective To observe the clinical efficacy and side effects of CHOP regimen in the treatment of diffuse large B cell lymphoma (DLBCL) in Uighur (Uighur) and Han Chinese subtypes. Methods A total of 167 hospitalized Han Chinese patients with DLBCL diagnosed by pathology and at least 6 cycles of CHOP regimen for 6 years were collected and divided into two groups: GCB and non-GCB with Hans method, Efficacy and adverse reactions. Results The immunophenotype of DLBCL in Han nationality was significantly higher than that of GCB genotype in DLBCL. The curative effect of DLBCL in both Han and Han nationality was superior to that of nonGCB genotype. There was no significant difference in the effective rate of DLBCL between the two groups Adverse reactions of chemotherapy in the two groups were mainly gastrointestinal reactions, mild to moderate myelosuppression and neurotoxicity with similar incidence of adverse reactions. CONCLUSIONS: Conventional immune subtypes are important indicators for judging the short-term efficacy of DLBCL in Uygur and Han ethnicity. The efficacy of first-line CHOP regimen in both non-GCB patients is limited, and a more effective chemotherapy regimen is suggested.